Louis Garguilo's Articles

31. Lynn Cinelli's Wake-Up Call: Pharma's Forecasting Makes CDMOs Sick 4/28/2025

    Lynn Cinelli, VP Global Biologics Supply Chain at Bristol Myers Squibb, has been strategizing on why Pharma is so poor at forecasting demand. "The entities that feel the pressures most may be our CDMOs,” she says. She has a better way to go about it — and it starts with the patient.

32. Tariffs Won't Stop Drug-Candidate Licensing From China Biotechs 4/23/2025

    According to Global Data, the total deal value of U.S. licensing of innovator drug candidates from Chinese biopharma companies has surged since 2020. This is an area way upstream of the current tariff focus on manufacturing. But how this R&D trend and those tariffs play out will impact your U.S.-based CDMOs.

33. Is An Outsourced BD Model Gaining Traction At CDMOs? 4/21/2025

    Why did George Hlass found Pharma Expanse, roughly described as a “BD-for-hire organization”? He says it was born of experiences over a long career in the role of business development (BD) professional. In part two, Hlass describes how, since 2023, the demand for this service has taken him by surprise.

34. The Unsung Influencer: Why Your CDMO BD Contact Matters More Than You Think 4/14/2025

    You want the best shot at a successful CDMO selection, and subsequent relationship – one that thrives during the good times, and survives the stress of development and manufacturing challenges? Your CDMO’s business development (BD) professional is a good place to focus. Here's why.

35. What If The Trump Tariff Strategy Works? 4/8/2025

    Doom and gloom in the drug development and manufacturing supply chain.  Predictions of disruptions and displacements. The Trump tariff ploy will fail, and costs/prices will skyrocket. But have you considered this “risk”? The tariff tantrum lowers national export/import duties for the entire globe.

36. What Biotechs Learn From Takeda's Internal Manufacturing Competition 4/7/2025

    Biotechs can learn about outsourcing facility selection from a pharma company like Takeda, who evaluates both internal and external locations to place its development and manufacturing projects. This is part two of Chief Editor Louis Garguilo's discussion with Takeda Linz's Roland Fabris.

37. Takeda's Award-Winning Facility Teaches You About Outsourcing 4/3/2025

    A Takeda production site in Linz, Austria, received an ISPE’s 2024 Facility of The Year Award. What’s so special about that location? The explanation from Roland Fabris, Site Head, will actually help you benchmark your CDMO, and demonstrate much about facility selection applicable to your own outsourcing needs. 

38. Pain And Pleasure In Project Management Of CDMOs 3/17/2025

    Tony Sampognaro of Stoke Therapeutics, says, “We're having to rearrange and bolster the constellation of CDMOs we're working with." The nice thing is, Stoke has a comprehensive extended enterprise model. Nonetheless, an all-outsourced model “can add hidden complexity." Here's how to manage that.

39. 'Fractional Hiring' At Your CDMO. Okay With You? 3/14/2025

    We need a flexible hiring marketplace – a new ecosystem – to generate increased awareness by professionals and students of positions in the biopharma industry. “It’s no longer about simply posting full-time jobs,” says Chris Frew, Founder/CEO of BioBuzz Networks. But is "fractional hiring" the answer?

40. Talent Logistics Turns Biotech Winter To Hiring Spring 3/3/2025

    After our "Biotech Winter" – a period starting circa 2021 with tens of thousands of layoffs and stagnating investment — is it springtime for biotech? Chris Frew, Founder/CEO of BioBuzz Networks, says yes. “We have demonstrably entered a turning point in biotech hiring.”